Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
1 treatment and condition followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |